Answers are grounded in this paper and cite their sources.
The combination of fenofibrate and simvastatin did not reduce the rate of fatal cardiovascular events, nonfatal myocardial infarction, or nonfatal stroke, as compared with simvastatin alone. These results do not support the routine use of combination therapy with fenofibrate and simvastatin to reduce cardiovascular risk in the majority of high-risk patients with type 2 diabetes. (ClinicalTrials.gov number, NCT00000620.)
No takes yet. Share an insight, caveat, or question.
Henry N. Ginsberg (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: